Trial Information
Phase 3 Study of Etoposide, Cisplatin, and Radiotherapy Versus Paclitaxel, Carboplatin and Radiotherapy in Patients With Unresectable Locally Advanced, Stage III Non-Small Cell Lung Cancer
Inclusion Criteria:
1. Inoperable stage IIIA/IIIB NSCLC proved by pathology or cytology
2. Age 18 to 75, ECOG ≤ 2, lose weight <10% during 6 months
3. No serious diseases of important organs
4. Chest CT in recently 4 weeks
5. No other tumor disease except stage I cervical cancer or cutaneous basal cell
carcinoma
6. Sign consent
7. Measurable lesion
Exclusion Criteria:
1. Pretreatment radiotherapy or chemotherapy
2. Pregnant or lactation woman
3. Serious diseases (include uncontrolled diabetes and infection) of important organs
4. Psychopath
5. Join in other clinical trial
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Overall Survival
Outcome Time Frame:
2 years
Safety Issue:
No
Principal Investigator
luhua Wang, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Department of Radiation Oncology, Cancer Hospital & Institution, CAMS & PUMC
Authority:
China:Chinese Academy of Medical Sciences
Study ID:
2006BAI02A02[1]-03
NCT ID:
NCT01494558
Start Date:
May 2007
Completion Date:
August 2011
Related Keywords:
- Non-Small Cell Lung Cancer
- Overall survival
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms